MMSI Merit Medical Systems Inc.

Fred Lampropoulos Receives Manufacturing Leader of the Year Award from the Utah Manufacturers Association 

Fred Lampropoulos Receives Manufacturing Leader of the Year Award from the Utah Manufacturers Association 

SOUTH JORDAN, Utah, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced that Fred Lampropoulos, Merit’s Chairman and CEO, received the 2022 Manufacturing Leader of the Year Award in the large manufacturing category from the Utah Manufacturers Association. The award honors excellence and tremendous efforts made by outstanding leaders and companies in the state of Utah. Mr. Lampropoulos accepted the award at a ceremony held at The Little America Hotel in Salt Lake City, UT.

Mr. Lampropoulos founded Merit over thirty years ago, and the company has become a leader in the manufacturing industry, designing and manufacturing lifesaving medical devices in Utah ever since. As Merit grew, its manufacturing footprint expanded to include facilities around the globe. Operational excellence is essential to Merit’s success. Each of its manufacturing facilities maintains one or more ISO certifications—international gold standards agreed upon by industry experts—in the areas of environment, energy, and occupational health and safety management. This design and manufacturing strategy has helped Merit grow to become one of the largest companies in Utah, broadening its global presence and helping it reach more than $1 billion in revenue. 

“This award acknowledges Fred’s significant leadership in our industry,” said Todd Bingham, President, and CEO of the Utah Manufacturers Association. “He is a pillar of the community and sets an example that many organizations look up to.”

Upon receiving the award, Mr. Lampropoulos said, “I am honored to accept this award on behalf of the entire Merit family. This award recognizes their hard work and dedication.” He added, “Receiving this award is especially meaningful, as it has been a challenging year for manufacturers. We have faced supply chain interruptions, which only spurred us to find innovative ways to produce more of our own materials. By pivoting distribution efforts, we continued to deliver products to our customers, providing them with the solutions they need to care for their patients.”

ABOUT MERIT MEDICAL  

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 600 individuals. Merit employs approximately 6,800 people worldwide.

TRADEMARKS  

Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc. and its subsidiaries in the United States and other jurisdictions.  

  

CONTACTS  

PR/Media Inquiries  

Sarah Comstock 

Merit Medical  

|  

  

Investor Inquiries  

Mike Piccinino, CFA, IRC  

Westwicke - ICR  

|   



EN
22/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Merit Medical Systems Inc.

Merit Medical Systems Inc: 1 director

A director at Merit Medical Systems Inc sold 10,000 shares at 95.190USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

 PRESS RELEASE

Merit Medical Acquires Biolife Delaware, L.L.C.

Merit Medical Acquires Biolife Delaware, L.L.C. Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports.Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profileMerit reaffirms full-year 2025 financial guidance previously issued on April 24, 2025, and updates full-year 2025 financial guidance to include the projected impact from this acq...

 PRESS RELEASE

Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-I...

Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.Approval was supported by superior 12-month target lesion primary patency (70.1%) and access circuit primary patency (58.1%) in the randomized arm of the trial. SOUTH JORDAN, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the Wrapsody Cell-Impermeable Endoprosthesis (CIE) received regulator...

 PRESS RELEASE

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Ar...

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months. SOUTH JORDAN, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced that the 12-month results from the single-arm cohort of the WAVE trial were presented at the annual Charing Cross Symposium ...

 PRESS RELEASE

Merit Medical Reports First Quarter 2025 Results and Updates Full-Year...

Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance First Quarter Highlights† Reported revenue of $355.4 million, up 9.8%Constant currency revenue* and constant currency revenue, organic* up 10.9% and up 6.0%, respectivelyGAAP operating margin of 11.5%, compared to 11.1% in prior year periodNon-GAAP operating margin* of 19.3%, compared to 17.0% in prior year periodGAAP EPS $0.49, up 2.0%Non-GAAP EPS* $0.86, up 14.8%Free cash flow* generation of $19.5 million, down 20.5% † Comparisons above are calculated for the current quarter compared with the first quarter o...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch